Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule5635（c）（4）-September18203
已发布：Sep182023
BRISBANE，Calif.，Sept.182023（GLOBE NEWSWIRE）--Annexon，Inc。（Nasdaq:ANNX），aclinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune，neurodegenerative and ophthalmic disorders，today announced that it has granted inducement to anewnon-executive employee under the terms of the 2022 Employment Inducement Award Plan.The equity award was approved on September 142023，in accordance with Nasdaq Listing Rule5635（c）（4）。
The new non-executive employee received an option to purchase 130000 shares of Annexon common stock.The option carries a ten-year term and an exercise price per share equal to$2.53，which was the closing price of Annexon’s common stock on September 15203，the date of grant，and vest over4years，with25%of the shares underlying the options vesting on the first anniversary of the grant date and an additional1/48 of the shares vesting monthly thereafter，subject to continued service through the applicable vesting dates。
About Annexon
Annexon（Nasdaq:ANNX）is a clinical-stage biopharmaceutical company that aims to bring game-changing medicines to patients with classical complement-mediated diseases of the body，brain and eye.The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune，neurodegenerative and ophthalmic diseases.Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathnet cont，while selectively preserving the beneficial immune functions of other complement pathways.Annexon is rigorously developine a pipeline of diversified product candidates across multiple mid-tolate-stage clinical trials，with clinical data anticipated throughout2023and beyond。
